# Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants

> **NCT04041674** · PHASE1 · WITHDRAWN · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)**

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** GEO-D02 DNA
- **BIOLOGICAL:** MVA/HIV62B Vaccine
- **BIOLOGICAL:** B63521^11 gp120
- **BIOLOGICAL:** IHV01 Protein
- **BIOLOGICAL:** Protein Placebo

## Key facts

- **NCT ID:** NCT04041674
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-01
- **Primary completion:** 2022-09-30
- **Final completion:** 2023-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Protocol undergoing additional revisions.
- **Last updated:** 2021-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04041674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04041674, "Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04041674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*